RG
LCTX icon

Rathbones Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Rathbones Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55.3K Hold
35,000
– – ﹤0.01% 633
2025
Q4 		$58.5K Hold
35,000
– – ﹤0.01% 619
2025
Q3 		$59.1K Hold
35,000
– – ﹤0.01% 622
2025
Q2 		$31.8K Hold
35,000
– – ﹤0.01% 616
2025
Q1 		$15.8K Hold
35,000
– – ﹤0.01% 596
2024
Q4 		$17.6K Hold
35,000
– – ﹤0.01% 602
2024
Q3 		$31.7K Hold
35,000
– – ﹤0.01% 594
2024
Q2 		$34.9K Hold
35,000
– – ﹤0.01% 600
2024
Q1 		$51.8K Hold
35,000
– – ﹤0.01% 591
2023
Q4 		$38.1K Hold
35,000
– – ﹤0.01% 590
2023
Q3 		$41.3K Buy
+35,000
New +$47.6K ﹤0.01% 597

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $3.03B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $93.4B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return